Trials / Recruiting
RecruitingNCT06830850
A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer
A Phase I, Open-label, Multi-Center, Non-Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- Atridia Pty Ltd. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of 5041-103 in Subjects with Metastatic Castration-resistant Prostate Cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS-5041 Single dose of HRS-5041 orally administered | HRS-5041 Oral dosage (Tablet) Oral dosage administration, 28 days per cycle. |
Timeline
- Start date
- 2025-06-15
- Primary completion
- 2026-12-30
- Completion
- 2027-03-15
- First posted
- 2025-02-17
- Last updated
- 2026-01-15
Locations
11 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT06830850. Inclusion in this directory is not an endorsement.